GLP-1 Drugs Cut Substance Use Disorder Odds by Up to 75% in 142,000-Patient Study
Updated
Updated · News18 · Jun 25
GLP-1 Drugs Cut Substance Use Disorder Odds by Up to 75% in 142,000-Patient Study
3 articles · Updated · News18 · Jun 25
Summary
A 2026 University of Texas at El Paso study of more than 142,000 obesity and type 2 diabetes patients linked GLP-1 drugs to sharply lower odds of developing several substance use disorders.
Among roughly 20,000 patients prescribed GLP-1s, researchers found 74% lower odds of alcohol use disorder, 69% for opioid use disorder, 68% for nicotine use disorder and 75% for cocaine use disorder.
The findings add to earlier human and animal evidence that drugs such as Ozempic and Wegovy may curb cravings by altering brain reward pathways, including GLP-1 receptor activity tied to dopamine signaling.
Researchers stressed the study was observational, not proof of causation, and said randomized trials are still needed before GLP-1 medicines can be recommended or approved for addiction treatment.
Did Ozempic really slash addiction risk by 75%, or does the groundbreaking study hide a simpler truth?
As Ozempic is hailed for curbing addiction, are we ignoring its serious health risks and lack of approval?
Pills vs. sound waves: Will drugs like Ozempic or focused ultrasound become the future of addiction treatment?
GLP-1 Receptor Agonists Reduce Odds of Alcohol and Opioid Use Disorders by Over 70%: Emerging Evidence, Mechanisms, and Future Directions
Overview
Emerging evidence shows that GLP-1 receptor agonists (GLP-1 RAs), originally used for diabetes and weight management, are now demonstrating significant promise in treating substance use disorders (SUDs), especially alcohol and opioid use disorders. Recent clinical trials and large-scale studies reveal that GLP-1 RAs, such as semaglutide, can effectively reduce heavy drinking and are linked to a much lower risk of developing alcohol use disorder. These medications offer a novel approach, working through brain reward pathways distinct from current treatments, and could become a new and effective option for people struggling with addiction.